Compare J M Smucker Co (SJM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Zoetis Inc — how do they compare? J M Smucker Co trades at $123.61 (market cap $13.17B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc is far larger — about 2.3× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| SJM | ZTS | |
|---|---|---|
Market Cap | $13.17B | $30.29B |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $150.61 |
52-Week Low | $89.53 | $71.91 |
Enterprise Value | $20.03B | $37.86B |
Dividend Yield | 3.63% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal from moving averages but bearish oscillators. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.24 surpassing the $2.22 estimate. The company reported a net loss of $1.23 billion for 2025, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $144.78 price target, indicating potential upside. A dividend of $1.12 per share is scheduled for payment on September 1, 2026.
The outlook is cautiously optimistic, driven by strong earnings performance and raised guidance, but high valuation ratios and recent insider sales pose risks. Debt levels remain elevated with a debt-to-asset ratio of 43.71% in 2025. Investors should weigh robust operational cash flow against margin pressures and competitive challenges in the consumer staples sector.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
